Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Responsiveness in Advanced or Metastatic Malignant Melanoma (SYS-ACT)

NCT02177110 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT02177110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02177110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Responsiveness in Advanced or Metastatic Malignant Melanoma (SYS-ACT)
Lead sponsor
Cancer Trials Ireland
Phase
Observational
Overall status
Completed
Start date
September 30, 2014
Completion date
Not reported
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, metastatic melanoma